Education
About Us
Working with TipRanks
Follow Us
Valneva (VALN)
NASDAQ:VALN
VALN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.62 - $9.50
Previous CloseN/A
Volume18.63K
Average Volume (3M)69.94K
Market Cap
$633.47M
Enterprise Value$539.83M
Total Cash (Recent Filing)€254.49M
Total Debt (Recent Filing)€152.73M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Mar 20, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding81,260,765
10 Day Avg. Volume93,841
30 Day Avg. Volume69,943
Standard Deviation0.24
R-Squared0.16
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.90
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$17.00Price Target Upside138.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Valneva News
PremiumCompany Announcements
Valneva Gains EMA Support for Chikungunya Vaccine Extension
PremiumCompany Announcements
Valneva Reports 2024 Financial Performance and Optimistic 2025 Outlook
---
Bulls Say, Bears Say
Bulls Say
Funding And InvestmentValneva announced that it received a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) providing Valneva with up to $41.3M of additional funding over the next five years.
Product Sales GrowthValneva's product sales rose 13% compared to the previous year, indicating solid growth.
Regulatory ApprovalsIxchiq receives approval in the UK, indicating progress in regulatory acceptance.
Bears Say
Revenue And EPS EstimatesValneva is lowering its 2025 revenue and EPS estimates, indicating challenges in meeting previous expectations.
Sales EstimatesIxchiq sales estimate for 2024 is lowered from €4M to €3M.
Sales ForecastIxchiq sales ramp slower than forecast, impacting overall expectations.
---
Ownership Overview
―
Insiders
0.15%
Mutual Funds
0.06% Other Institutional Investors
99.80% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VALN FAQ
What was Valneva’s price range in the past 12 months?
Valneva lowest stock price was $3.62 and its highest was $9.50 in the past 12 months.
What is Valneva’s market cap?
Valneva’s market cap is $633.47M.
When is Valneva’s upcoming earnings report date?
Valneva’s upcoming earnings report date is Mar 20, 2025 which is in 20 days.
How were Valneva’s earnings last quarter?
Valneva released its earnings results on Nov 07, 2024. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.266 by $0.156.
Is Valneva overvalued?
According to Wall Street analysts Valneva’s price is currently Undervalued.
Does Valneva pay dividends?
Valneva does not currently pay dividends.
What is Valneva’s EPS estimate?
Valneva’s EPS estimate is -0.19.
How many shares outstanding does Valneva have?
Valneva has 81,260,765 shares outstanding.
What happened to Valneva’s price movement after its last earnings report?
Valneva reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.266. Following the earnings report the stock price went down -1.968%.
Which hedge fund is a major shareholder of Valneva?
Currently, no hedge funds are holding shares in VALN
---
Valneva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (138.76% Upside)
$17.00 (138.76% Upside)
Blogger Sentiment
Bullish
VALN Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 11.4%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.99%
12-Months-Change
Fundamentals
Return on Equity
-3.73%
Trailing 12-Months
Asset Growth
4.62%
Trailing 12-Months
Company Description
Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally.
---
VALN Company Deck
---
VALN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
Valneva's earnings call reflects a balanced view with strong product sales growth, a positive financial turnaround, and strategic advancements in R&D. However, challenges persist with the slow uptake of IXCHIQ in the US and increased costs impacting margins. The company is optimistic about future growth prospects and sustained profitability from 2027 onwards.Read More>---
VALN Stock 12 Month Forecast
Average Price Target
$17.00
▲(138.76% Upside)
Technical Analysis
Best Analysts Covering VALN
1 Year
1 Year Success Rate
5/24 ratings generated profit
1 Year Average Return
-17.25%
reiterated a buy rating 21 hours ago
Copying Edward White's trades and holding each position for 1 Year would result in 20.83% of your transactions generating a profit, with an average return of -17.25% per trade.
---